New study tests Anti-Inflammatory drug for Crohn's in china

NCT ID NCT07663526

Not yet recruiting Disease control Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study will test the drug Tabellvi (adalimumab) in 50 Chinese adults with moderate to severe Crohn's disease. The goal is to see how safe and effective it is in real-world settings, focusing on side effects and whether patients achieve remission after 26 weeks. Participants must have failed other treatments like steroids or immunosuppressants.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Adalimumab (Tabellvi), a drug that blocks inflammation
What this could lead to: If successful, this could confirm that adalimumab works well and safely for Chinese patients with Crohn's disease in everyday medical practice.
What could go wrong: This is a small, single-arm study with no comparison group, so results may not be definitive. Side effects like infections or allergic reactions are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN'S DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN'S DISEASE

Contacts and locations

Locations

Fuyang People's Hospital

Fuyang, Anhui, 236000, China
Huai'an First People's Hospital

Huaian, Jiangsu, 223001, China
Meihekou Central Hospital

Meihekou, Jilin, 135022, China
Shanghai Jiao Tong University School of Medicine, Renji Hospital

Shanghai, Shanghai Municipality, 200001, China
The Second Affiliated Hospital of Zhengzhou University

Zhengzhou, Henan, 450014, China
Yancheng No.1 People's Hospital

Yancheng, Jiangsu, 224500, China
Zhoukou Central Hospital

Zhoukou, Henan, 466000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.